Biosimilar Interleukins Market Report 2026
Global Outlook – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes) – Market Size, Trends, Strategies, and Forecast to 2030
Biosimilar Interleukins Market Overview
• Biosimilar Interleukins market size has reached to $7.52 billion in 2025 • Expected to grow to $41.22 billion in 2030 at a compound annual growth rate (CAGR) of 40.6% • Growth Driver: Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market • Market Trend: Biogen Launches An Innovative Biologic Treatment • North America was the largest region in 2025.What Is Covered Under Biosimilar Interleukins Market?
Biosimilar interleukins are defined as biosimilars produced by the body's leukocytes (white blood cells). Immune reactions are controlled by interleukins. Laboratory-produced interleukins are used as biological response modifiers to strengthen the immune system in cancer treatment. The different types of biosimilar interleukins are IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and others, and are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, clinics, and research institutes.
What Is The Biosimilar Interleukins Market Size and Share 2026?
The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $7.52 billion in 2025 to $10.54 billion in 2026 at a compound annual growth rate (CAGR) of 40.2%. The growth in the historic period can be attributed to high cost of originator interleukin biologics, increasing prevalence of autoimmune and inflammatory diseases, growing burden of rheumatoid arthritis and psoriasis, limited patient access to biologic therapies, rising awareness of biologics in immune modulation.What Is The Biosimilar Interleukins Market Growth Forecast?
The biosimilar interleukins market size is expected to see exponential growth in the next few years. It will grow to $41.22 billion in 2030 at a compound annual growth rate (CAGR) of 40.6%. The growth in the forecast period can be attributed to patent expirations of branded interleukins, expansion of biosimilar clinical pipelines, increasing physician acceptance of biosimilars, supportive government policies for biosimilar use, rising demand for affordable biologic cancer and immunology treatments. Major trends in the forecast period include rising adoption of biosimilar interleukins in autoimmune disease treatment, increasing demand for cost-effective alternatives to originator biologics, expansion of biosimilar approvals across multiple indications, growing use of interleukins in chronic inflammatory disorders, strengthening regulatory frameworks supporting biosimilar adoption.
Global Biosimilar Interleukins Market Segmentation
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes Subsegments: 1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management 2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment 3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders 4) By IL-5: Asthma Treatment, Eosinophilic Disorders 5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease TreatmentWhat Is The Driver Of The Biosimilar Interleukins Market?
The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefits in regulating the cells, and in directing proliferation, activation, and migration of the cells. For instance, in February 2024, according to reports published by the National Institutes of Health (NIH), a US-based biomedical research agency, the estimated annual increases in the global incidence and prevalence of autoimmune diseases are 19.1% and 12.5%, respectively. Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins industry and is expected to drive the growth of the market.Key Players In The Global Biosimilar Interleukins Market
Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Biosimilar Interleukins Market Trends and Insights
Major companies operating in the biosimilar interleukins market are innovating new products such as Tofidence (tocilizumab-bavi) to increase their profitability in the market. Tofidence is a monoclonal antibody that targets and attaches to interleukin-6 receptors, employed in the treatment of various inflammatory autoimmune disorders. For instance, in September 2023, Biogen Inc., a US-based biotechnology company got approval from the FDA for Tofidence (tocilizumab-bavi) as the first biosimilar to reference Genentech's Actemra (tocilizumab). Tofidence is administered through intravenous infusion and has received approval for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.What Are Latest Mergers And Acquisitions In The Biosimilar Interleukins Market?
In August 2025, Bio-Thera Solutions, a China-based biopharmaceutical company, extended its biosimilars alliance with STADA Arzneimittel to include tocilizumab. This expansion aims to strengthen the partners’ biosimilar portfolios, enhance market access to cost-effective immunology treatments, and support broader global distribution of high-quality biologic alternatives. STADA Arzneimittel, a Germany-based pharmaceutical company, focuses on providing high-value generics, biosimilars, and consumer healthcare products.
Regional Insights
North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Biosimilar Interleukins Market?
The biosimilar interleukins market consists of sales of mabPharm, gedeonrichter, and bio-thera solutions. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Biosimilar Interleukins Market Report 2026?
The biosimilar interleukins market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar interleukins industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Biosimilar Interleukins Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $10.54 billion |
| Revenue Forecast In 2030 | $41.22 billion |
| Growth Rate | CAGR of 40.2% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Application, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |